There is a correlation between the high expression of GHET1 and the poor gemcitabine sensitivity in patients with breast cancer, and the knockdown of GHET1 is related with an increase in gemcitabine-induced cytotoxicity (Li B. et al., 2019). The gene discussed is GHET1; the disease is breast carcinoma.